BMY240726C30000
- 12.62
- 0.000.00%
Bristol-Myers Squibb Newsroom
Express News | Cantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $45 Price Target
Bristol-Myers Squibb Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 5.07% Cantor Fitzgerald $45 → $45 Reiterates Neutral → Neutral 07/10/2024 -4.27% Barclays $43 →
Express News | Bristol-Myers Squibb Co : Jefferies Cuts Target Price to $49 From $54
Trump Media, CrowdStrike, Tesla, Verizon, Ryanair, and More Stock Market Movers
Trump Media stock rises after President Biden ends his run for reelection, CrowdStrike extends losses after the global IT outage on Friday, Verizon reports earnings Monday, and Tesla issues its profit report on Tuesday.
Kamala Harris' Potential Impact on Health Care Stocks
With President Joe Biden earlier Sunday saying he will end his campaign for re-election and endorsing Vice President Kamala Harris, the focus now turns on her positions on issues.
Investors in Bristol-Myers Squibb (NYSE:BMY) From Three Years Ago Are Still Down 30%, Even After 5.4% Gain This Past Week
Here Are Big Pharma's Leading Blockbuster Makers
What to Expect in the Week Ahead (Google and Tesla Earnings; GDP and PCE Data)
This week, investors should keep an eye on earnings reports from several key players, including Google and Tesla. Key economic data to watch for will include the release of the first estimate of second-quarter gross domestic product and the Federal Reserve's preferred inflation measure for June.
Tesla, AT&T, Alphabet, Chipotle, Visa, and More Stocks to Watch This Week
Second-quarter earnings season continues with Verizon, Alphabet, Coca-Cola, Comcast, General Motors, Tesla, Visa, AT&T, Chipotle, and Newmont.
Financials Dominate in Q2 as Wall Street Slides Amidst Concerns on Tech - Earnings Scorecard
Preview -- Barron's
Monday 7/22 Big Tech, including two of the Magnificent Seven, headline earnings this week. SAP releases quarterly results on Monday, followed by Alphabet and Tesla on Tuesday. IBM announces earnings
At Long Last, the 'Other S&P 500' Takes a Bow
The S&P 500 index has long been a stand-in for "the stock market" among investors. But with the Magnificent Seven tech stocks playing such an outsize role, more people are talking about -- and putting money behind -- an alternative version.
Catalyst Watch: Earnings Deluge, Farnborough Airshow, Paris Olympics, and Trump Talks Crypto
Stocks to Watch Next Week: Tesla, Microsoft, Alphabet and Amazon
Bristol Myers' Immunotherapy Combo Undergoes EU Review for Liver Cancer
What Are the Most Profitable Stocks of All Time? The Answer Might Surprise You.
An academic with a large following on Wall Street recently published a paper showing the stocks that have seen the strongest returns over time
Express News | Bristol Myers Squibb Says EMA Validated Its Type II Variation Application For Opdivo Plus Yervoy For First-Line Treatment Of Unresectable Or Advanced Hepatocellular Carcinoma
Express News | Bristol-Myers Squibb Co - No New Safety Signals Identified for Opdivo Plus Yervoy
Express News | Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma
What the Options Market Tells Us About Bristol-Myers Squibb
Deep-pocketed investors have adopted a bearish approach towards Bristol-Myers Squibb (NYSE:BMY), and it's something market players shouldn't ignore. Our tracking of public options records at